Fox Run Management’s ImmunityBio IBRX Stock Holding History

Fox Run Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,504	Closed	-$85.8K	–	1050
2024 Q4	$85.8K	Buy	+33,504	New	+$140K	0.02%	817

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fox Run Management's IBRX Position: Q1 2025 in Review

Fox Run Management sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 33,504 shares — an estimated $85.8K sold.

Fox Run Management first reported a position in IBRX in Q4 2024 and held it in 1 quarter. The position peaked at $85.8K in Q4 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

Fox Run Management reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
Fox Run Management sold 33,504 ImmunityBio shares in Q1 2025, an estimated $85.8K.
Fox Run Management first reported a position in ImmunityBio in Q4 2024 and held it in 1 quarter.
Fox Run Management's ImmunityBio position peaked at $85.8K in Q4 2024.
210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Fox Run Management's 13F filing for Q1 2025, filed 13 May 2025.